Today In History
Six-year-old Robert W. Patch granted a patent for a "toy truck".
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8158635 | Solid forms comprising 4-[9-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluoro-phenylamino)-9-purin-2-ylamino]-cyclohexan-1-ol, compositions thereof, and uses therewith Solid forms comprising 4-[9-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluoro-phenylamino)-9H-purin-2-ylamino]-cyclohexan-1-ol, compositions comprising the solid forms, methods of making the solid forms and methods of their use for the treatment of various diseases and/or ... | 04/17/2012 |
| 8084458 | Synthesis of locked nucleic acid derivatives Methods are described for the synthesis of Locked Nucleic Acid (LNA) derivatives using certain nitrogen-containing nucleophiles. ... | 12/27/2011 |
| 7977344 | Compounds The present invention includes novel compounds useful in the treatment of various disorders in particular infectious diseases, cancer, and allergic diseases and other inflammatory conditions for example allergic rhinitis and asthma, and as vaccine adjuvants. ... | 07/12/2011 |
| 7960397 | 6,9-disubstituted purine derivatives and their use as cosmetics and cosmetic compositions Certain 6,9-disubstituted purine derivatives and their pharmaceutically acceptable salts of the following general formula are provided wherein R6 and R9 are as defined in the specification. These 6,9-disubstituted purine de... | 06/14/2011 |
| 7807685 | Therapeutic compounds Compounds of formula (I) below are disclosed. Their use as medicaments is described, in particular for the treatment of pain or inflammation: wherein: when X=Y=Z=OH, R1 is OCH2CF2 | 10/05/2010 |
| 7572800 | Combination therapy to treat hepatitis B virus The present invention is directed to a method for treating hepatitis B virus infection in humans comprising administering a synergistically effective amount of agents having known anti-hepatitis B virus activity in combination or alternation. Specifically, the inven... | 08/11/2009 |
| 7569575 | Synthesis of locked nucleic acid derivatives The invention relates to a novel strategy for the synthesis of Locked Nucleic Acid derivatives, such as α-L-oxy-LNA, amino-LNA, α-L-amino-LNA, thio-LNA, α-L-thio-LNA, seleno-LNA and methylene LN... | 08/04/2009 |
| 7495006 | 2′ and 3′-substituted cyclobutyl nucleoside analogs for the treatment of viral infections and abnormal cellular proliferation Provided are cyclobutyl nucleosides and methods for their use in treatment of infections including Retroviridae (including HIV), Hepadnaviridae (including HBV), or Flaviviridae (including BVDV and HCV) infection, or conditions related to abnormal cellular proliferat... | 02/24/2009 |
| 7423041 | A1 adenosine receptor antagonists Compounds of the general formula (I) are described: wherein A is a 5- or 6-membered aromatic or heteroaromatic ring. Compositions comprising such compounds and methods of use thereof are also described. ... | 09/09/2008 |
| 7420056 | Substituted bicyclic imidazo-3-ylamine compounds Substituted bicyclic imidazo-3-yl-amine compounds are provided, as well as processes for the production thereof and pharmaceutical formulations containing these compounds. The use of these compounds for the production of pharmaceutical formulations and related metho... | 09/02/2008 |
| 7407955 | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions The present invention relates to substituted xanthines of general formula wherein R1 to R3 are defined as in claims 1 to 16, the tautomers, the stereoisomers, the mixtures, the prodrugs t... | 08/05/2008 |
| 7388002 | Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases Compounds represented by the formula: A is (CH2)nR2, —CH═CH2, CH2—CH═CH2, O(CH2)nR2, CH(OH)CH3, CH(OH)... | 06/17/2008 |
| 7335654 | Phosphodiesterase 4 inhibitors PDE4 inhibition is achieved by novel compounds of the Formula I: wherein R1 and R2 are as defined herein. ... | 02/26/2008 |
| 7291623 | Compounds that interact with kinases A method of inhibiting or effecting the activity of protein kinase activity which comprises contacting a protein kinase with a compound of formula (I) being a derivative of a furanose or pyranose form of a monosaccharide, or a pharmaceutically acceptable salt thereo... | 11/06/2007 |
| 7279482 | Heterocyclic compound based on N-substituted adenine, methods, of their preparation, their use for preparation of drugs, cosmetic preparations and growth regulators, pharmaceutical preparations, cosmetic preparations and growth regulators containing these compounds Heterocyclic derivatives based on N6-substituted adenine of, e.g.,a formula: wherein R2 is hydrogen, R6 is R6′-X, X is —NH—, and R6′ is substituted phenyl or substituted benzyl. The derivatives... | 10/09/2007 |
| 7268141 | Xanthine phosphodiesterase V inhibitors A xanthine phosphodiesterase V inhibitor having the formula (I), with the variables defined herein, which is especially useful for treating male (erectile) and female sexual dysfunction and other physiological disorders: | 09/11/2007 |
| 7256196 | Purine cytokine inhibitors The present invention relates to 2,8,9-substituted purines which inhibit the extracellular release of inflammatory cytokines, said cytokines responsible for one or more human or higher mammalian disease states. The present invention further relates to compositions c... | 08/14/2007 |
| 7247639 | A1 adenosine receptor antagonists The present invention provides novel adenosine receptor antagonists, more particularly, A1 adenosine receptor antagonists of formula (I). Pharmaceutical compositions comprising an A1 adenosine receptor antagonist of formula (I) and a pharmaceut... | 07/24/2007 |
| 7238700 | Aadenosine receptor antagonists Disclosed are novel A2B adenosine receptor antagonists of Formula I: A compound of the formula: wherein: R1 is... | 07/03/2007 |
| 7217702 | Selective antagonists of A2A adenosine receptors Selective antagonists of A2A adenosine receptors like those of formula I are provided, wherein Y forms a ring. The novel A2A blockers are useful for the treatment of Parkinsons disease and o... | 05/15/2007 |
| 7202252 | Aadenosine receptor antagonists Compounds of the general formula (I) are described: wherein A is a 5- or 6-membered aromatic or heteroaromatic ring. Compositions comprising such compounds and methods of use thereof are also described. ... | 04/10/2007 |
| 7199127 | Purine nucleosides Disclosed are purine nucleoside compounds that are selective to A3 adenosine receptors and are useful for the treatment of cancer and inflammatory diseases. The compounds are shown by the following general formula (I), including isomers thereof: | 04/03/2007 |
| 7189730 | Aadenosine receptor antagonists Disclosed are novel A2A adenosine receptor antagonists of the formula: wherein: R1 is optionally substituted aryl or optionally substituted heteroaryl; | 03/13/2007 |
| 7157465 | Adenine derivatives This invention relates to an adenine derivative, a tautomer thereof, or a pharmaceutically acceptable salt thereof represented by general formula (I): wherein X represents NR3 (wherein R3 re... | 01/02/2007 |
| 7148226 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same The invention relates to compounds of the formula 1 and to pharmaceutically acceptable salts, solvates, prodrugs and metabolites thereof, wherein W, Z, R1 and R2, are as defined herein. The ... | 12/12/2006 |
| 7148229 | Sulfonamide substituted xanthine derivatives The present invention is a sulfonamide substituted xanthine derivative of formula I: or a pharmaceutically acceptable salt thereof, wherein R1 is lower alkyl, lower alkyl substituted by phenyl, or lower alkyl sub... | 12/12/2006 |
| 7135475 | Amide substituted xanthine derivatives The present invention is a 1,3,8 substituted xanthine derivative of formula I or a pharmaceutically acceptable salt thereof, wherein R1, R2 and R3 are as defined in the specificat... | 11/14/2006 |
| 7129239 | Purine compounds and uses thereof Compounds of Formula (I) that act as cannabinoid receptor ligands and their uses in the treatment of diseases linked to the mediation of the cannabinoid receptors in animals are described herein. ... | 10/31/2006 |
| 7086397 | Patient usable emergency medical kit The invention provides an emergency medical kit for use immediately upon the onset of symptoms of an attack of a vascular disease such as a heart attack or a stroke. The emergency medical kit at least includes breathable oxygen in a light weight container and may in... | 08/08/2006 |
| 7074923 | Process for preparing xanthine phosphodiesterase V inhibitors and precursors thereof A process for preparing xanthine phosphodiesterase V inhibitors, and compounds utilized in said process. The process includes a five-step methodology for efficient synthesis of Compound 5 without intermediate purifications or separations, a dihalogenation step to sy... | 07/11/2006 |
| 7052891 | Human lysophoshatidic acid acyltransferase gamma-1 polypeptide Polypeptides are obtained, for example, via expression of encoding cDNA sequences, that have the activity of the enzyme lysophosphatidic acid acyltransferase (LPAAT), also known as 1-acyl sn-glycerol-3-phosphate acyltransferase. ... | 05/30/2006 |
| 7045327 | Human lysophosphatidic acid acyltransferase gamma-2 polypeptide Polypeptides are obtained, for example, via expression of encoding cDNA sequences, that have the activity of the enzyme lysophosphatidic acid acyltransferase (LPAAT), also known as 1-acyl sn-glycerol-3-phosphate acyltransferase. ... | 05/16/2006 |
| 7005425 | Method for treating arrhythmias Methods are provided for treating arrhythmia in a manner that minimizes undesirable side effects, comprising administration of a therapeutically effective minimal dose of an A1 adenosine receptor agonist with a therapeutically effective minimal dose of a ... | 02/28/2006 |
| 7001910 | Thiazolidinedione derivatives as antidiabetic agents The present invention refers to compounds of the general formula (I), to their possible pharmaceutically acceptable salts and tautomeric forms. The present invention also refers to a process for their production and to their use as antidiabetic and *hypoglycemic age... | 02/21/2006 |
| 6969720 | Biaryl substituted purine derivatives as potent antiproliferative agents The compounds of the present invention are 2,6,9-trisubstituted purine derivatives which are inhibitors of cyclin/cdk complexes. The compounds of the current invention also are potent inhibitors of human cellular proliferation. As such, the compounds of the present ... | 11/29/2005 |
| 6936602 | Benzazepine derivatives, process for the preparation of the same and uses thereof Compounds of the general formula (I): or salts thereof, which exhibit CCR5 antagonism and exert preventive and therapeutic effects against HIV infections: wherein R1 is a 5- to 6-membered aromatic ring which... | 08/30/2005 |
| 6894040 | Xanthine phosphodiesterase V inhibitors A xanthine phosphodiesterase V inhibitor having the formula (I), with the variables defined herein, which is especially useful for treating male (erectile) and female sexual dysfunction and other physiological disorders: | 05/17/2005 |
| 6887880 | Adenine based inhibitors of adenylyl cyclase, pharmaceutical compositions, and method of use thereof The present invention relates to derivatives and analogues of adenine of the formula: wherein L, A, Y and Z are those defined herein. Compounds of the present invention are useful in inhibiting adenylyl cyclase activit... | 05/03/2005 |
| 6849660 | Antimicrobial biaryl compounds Provided are antibacterial compounds having Formula I: In such compositions, X is O or S; Y is CH2; n is 0 or 1. One of R1 and R1′ is —C(O)NR5R5′ | 02/01/2005 |
| 6812232 | Heterocycle substituted purine derivatives as potent antiproliferative agents The compounds of the present invention are 2,6,9-trisubstituted purine derivatives which are inhibitors of cyclin/cdk complexes. The compounds of the current invention also are potent inhibitors of human cellular proliferation. As such, the compounds of the present ... | 11/02/2004 |
